Orforglipron Results: Weight Loss Timeline and Trial Data

In the Phase 3 ATTAIN-1 trial, people taking the highest dose of orforglipron lost around 11.1% to 12.4% of their starting body weight after 72 weeks.

This means that a person weighing 100kg could lose around 11–12kg on average over the course of the trial. However, this is only an average. Some people may lose more, while others may lose less.

Individual results can depend on:

• starting weight
• dose reached
• appetite response
• side effects
• diet
• physical activity
• medical history
• whether treatment is continued long term

The strongest evidence for orforglipron comes from Phase 2 and Phase 3 clinical trials.

Study sources: Phase 2 obesity trial published in the New England Journal of Medicine: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity, and Phase 3 ATTAIN-1 trial: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity.

The Phase 2 trial showed strong results over 36 weeks. The larger Phase 3 ATTAIN-1 trial is more useful for setting realistic expectations because it followed people for longer.

Based on current evidence, the most realistic expectation is average weight loss of around 11–12.4% over 72 weeks at the highest dose.

Orforglipron does not usually cause immediate weight loss. Results tend to build gradually as treatment continues and the dose is increased.

The published trial data does not provide exact average weight loss figures for every individual month.

The strongest published results are measured at 26 weeks, 36 weeks and 72 weeks. For this reason, the timeline below should be used as a practical guide rather than a guaranteed prediction.

Early monthly figures are estimates based on available trial endpoints and dose escalation. Published trial results showed 8.6% to 12.6% weight loss at 26 weeks and 9.4% to 14.7% at 36 weeks in Phase 2 data, while Phase 3 ATTAIN-1 reported around 11.1% to 12.4% at 72 weeks.

Orforglipron weight loss after 1 month

After 1 month on orforglipron, weight loss is usually expected to be modest. This is because treatment starts at a low dose to help reduce the risk of gastrointestinal side effects.

Some people may notice reduced appetite, smaller portion sizes or feeling full sooner during the first month. However, it is too early to judge the full effect of orforglipron after only 4 weeks.

Orforglipron weight loss after 2 months

After 2 months, some people may start to see more visible changes in weight and appetite. By this stage, the dose may have been increased if treatment is tolerated.

However, orforglipron should still be viewed as a long-term treatment. A modest response after 2 months does not necessarily mean the medicine will not work, especially if a higher treatment dose has not yet been reached.

Orforglipron weight loss after 3 months

After 3 months, weight loss may become clearer for some people. Appetite suppression may be more consistent, and changes in eating habits may become easier to maintain.

There is no exact 3-month average result from the main obesity trials, but clinical data shows that meaningful weight loss continues to build over the first 6 to 9 months of treatment.

Orforglipron weight loss after 6 months

Six months is a more useful point for assessing early orforglipron results.

In the Phase 2 obesity trial, average weight loss at 26 weeks ranged from 8.6% to 12.6%, depending on the dose used. Placebo weight loss was around 2.0% at the same time point.

This suggests that people who respond well to treatment may see meaningful weight loss by around 6 months.

Orforglipron weight loss after 1 year

There is not a single published 1-year headline result from the main obesity trials. However, available data shows that weight loss continued beyond 36 weeks and remained clinically meaningful at 72 weeks.

By 1 year, people who tolerate orforglipron and continue treatment may have lost a meaningful amount of weight, particularly if they have reached an effective dose and maintained changes to diet and activity.

Orforglipron weight loss after 2 years

There is not yet enough published 2-year obesity data to give a reliable average weight loss figure for orforglipron after 2 years.

The main Phase 3 ATTAIN-1 trial measured results at 72 weeks, which is around 16.5 months. Longer-term data is needed to understand weight loss maintenance and outcomes beyond this point.

Orforglipron results vary from person to person. Some people respond strongly to GLP-1 medicines, while others lose less weight.

Results may be affected by:

• the dose reached
• how long treatment is continued
• appetite response
• calorie intake
• physical activity
• side effects
• other medicines
• underlying health conditions
• whether weight loss changes are maintained long term

Side effects can also affect results if they make it difficult to continue treatment or reach a higher dose.

Orforglipron has also been studied as a possible maintenance treatment after people have lost weight with injectable GLP-1 or GIP/GLP-1 medicines.

In the ATTAIN-MAINTAIN trial, people who switched to orforglipron maintained more of their previous weight loss than people switched to placebo.

This suggests orforglipron may have a future role in long-term weight management, although treatment decisions should always be made by a healthcare professional.

Take it consistently

Orforglipron is taken once daily. Missing doses regularly may reduce how well it works, especially for appetite control.

Follow the dosing schedule

GLP-1 medicines are usually increased gradually to improve tolerability and reduce side effects. Do not rush dose increases unless advised by your prescriber.

Further reading: Orforglipron dosage guide

Prioritise protein

Eating enough protein can help preserve muscle while losing weight. This is especially important if your appetite is much lower than usual.

Reduce high-fat and heavy meals

Greasy, rich or very large meals can make GLP-1 side effects worse, especially nausea, reflux, bloating and diarrhoea.

Stay hydrated

Reduced appetite can sometimes mean you eat and drink less without realising. Aim to drink regularly throughout the day.

Strength train where possible

Resistance training helps protect muscle mass during weight loss and can improve body composition.

Build long-term habits

The best results come when orforglipron is combined with sustainable habits. If you stop treatment and return to previous eating patterns, weight regain is possible.

Orforglipron results are promising, particularly because it is a tablet-based GLP-1 treatment.

In clinical trials, people taking the highest dose lost around 11.1% to 12.4% of their starting body weight over 72 weeks. Earlier Phase 2 data showed weight loss of 9.4% to 14.7% after 36 weeks, depending on dose.

Weight loss with orforglipron usually happens gradually. Some people may notice appetite changes within the first few weeks, but the most meaningful results are usually seen after several months.

Longer-term data is still needed to understand how well orforglipron results are maintained beyond 72 weeks.